Brisbane, CA, December 09, 2025 (Globe Newswire) -- Vera Therapeutics announced the pricing of an underwritten public offering of just over 6.1 million Class A shares at $42.50 per share, generating approximately $261 million in gross proceeds before fees. The company also granted underwriters a 30-day option to purchase up to an additional 920,716 shares, which could further increase the total raise. Proceeds are expected to support Vera’s late-stage clinical development p

Galway, Ireland, December 17, 2025 (Business Wire) -- AVeta Medical announced the appointment of Karen Noblett, M.D., as Chief Executive Officer, marking a leadership transition as the company advances its VITA AV™ platform for genitourinary syndrome of menopause. Noblett joins from Axonics, where she served as Chief Medical Officer and led clinical strategy, regulatory programs, and physician education supporting the global adoption of sacral neuromodulation technologies.

New York, NY, December 17, 2025 (Reuters) -- Medline shares surged 20.7% in their New York debut after the medical supplies company raised $6.26 billion in an upsized initial public offering, valuing the business at roughly $46 billion and making it the largest U.S. IPO since Rivian’s 2021 listing. Backed by Blackstone, Carlyle and Hellman & Friedman, Medline sold 216 million shares at $29 each, cementing the biggest private-equity-backed IPO on record and the largest globa

Tarrytown, NY and Somerville, MA, December 1, 2025 (Globe Newswire) -- Regeneron Pharmaceuticals and Tessera Therapeutics are collaborating to develop TSRA-196, an in vivo Gene Writing therapy targeting alpha-1 antitrypsin deficiency (AATD), a genetic disease affecting lungs and liver in roughly 200,000 people in the U.S. and Europe. The therapy aims to correct the underlying mutation and restore functional protein through a one-time durable treatment. Tessera will lead ini

Baar, Switzerland and Portsmouth, NH, December 3, 2025 (Business Wire) -- Novocure (NASDAQ: NVCR) named Frank Leonard as its new Chief Executive Officer, effective immediately, following the resignation of Ashley Cordova. Leonard, previously Novocure’s President, has spent over 15 years leading global business operations and helping launch the company’s device-based cancer therapies. William Doyle, Executive Chairman, highlighted Leonard’s pivotal role in shaping Novocure’s

St. Paul, MN, November 20, 2025 (PRNewswire) -- Solventum (NYSE: SOLV) will acquire Acera Surgical, a private bioscience company specializing in fully engineered materials for regenerative wound care, for $725 million in cash plus up to $125 million in milestone-based payments. Acera, founded in 2013, markets Restrata® products in the U.S., used to treat complex, hard-to-heal wounds in acute care settings. Read full article here .

New York, December 3, 2025 (PRNewswire) -- Baird Medical appointed Mark Saxton as CEO of its U.S. subsidiary, bringing over 25 years of medtech leadership including experience at NeuroPace, Smith + Nephew, and Covidien. Saxton will lead U.S. operations, driving the expansion of Baird’s minimally invasive Microwave Ablation (MWA) platform. Read full article here .

Chicago, IL, November 24, 2025 (finance yahoo) -- GE HealthCare (GEHC) announced it will acquire Intelerad, a cloud-based medical imaging software leader, in a $2.3 billion all-cash transaction. The acquisition expands GEHC’s cloud and AI-enabled imaging capabilities across inpatient and outpatient settings, supporting its long-term precision care strategy. The deal brings Intelerad’s outpatient expertise into GEHC’s hospital-focused portfolio, creating a more connected ent

Palo Alto, CA, November 3, 2025 (Business Wire) -- Hippocratic AI raised $126 million in a Series C round, bringing its total funding to $404 million and valuing the company at $3.5 billion. The round was led by Avenir Growth with participation from CapitalG, General Catalyst, Andreessen Horowitz, Kleiner Perkins, Premji Invest, and major health systems including UHS, Cincinnati Children’s, and WellSpan Health. The company plans to use the capital for global expansion, prod

New York, November 12, 2025 (Globe Newswire) -- Ovid Therapeutics unveiled a CEO succession plan in which Meg Alexander will become Chief Executive Officer and join the Board on January 1, 2026, while co-founder Dr. Jeremy Levin shifts to Executive Chairman. The announcement accompanied the company’s third-quarter 2025 financial results and updates on its pipeline progress. Alexander, who has played a key role in shaping the company’s strategy and operations since 2021, wil

New Haven, CT, November 17, 2025 (Reuters) -- Johnson & Johnson will acquire Halda Therapeutics in a $3.05 billion all-cash deal aimed at accelerating Halda’s RIPTAC™ platform for solid tumors. The lead candidate, HLD-0915, recently reported promising Phase 1/2 results in metastatic castration-resistant prostate cancer, showing good tolerability along with reductions in PSA levels and RECIST-based tumor responses. Halda’s broader pipeline includes multiple RIPTAC programs t

Sydney & Boston, November 17, 2025 (Business Wire) -- AdvanCell has appointed biopharma executive Philina Lee, PhD, as its new Chief Executive Officer, effective January 1, 2026. Based in the company’s new U.S. headquarters near Boston/Cambridge, she will spearhead the company’s American expansion while advancing clinical, manufacturing, and partnership efforts for its targeted alpha therapy pipeline. Dr. Lee brings extensive radiopharmaceutical and oncology experience, hav